

Evonile Pharma Limited

(formerly known as Novartis India Limited)

October 26, 2026

To,
BSE Limited
The Secretary,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

BSE Scrip Code: 500672

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 – Appointment of Senior Management Personnel (SMP)

Dear Sir/Madam,

We wish to inform you that, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), Mr. Gagan Sharma – President Specialty Business, is being designated as a Senior Management Personnel w.e.f. October 26, 2026.

The disclosure as required under the Regulation 30(6) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as **Annexure - A**.

We request you to kindly note and take the above information on record.

For **Evonile Pharma Limited**
(formerly known as Novartis India Limited)

CHANDNI
BHUPENDRA MARU
RA MARU

Digitally signed by
CHANDNI
BHUPENDRA MARU
Date: 2026.10.26
16:44:14 +05'30'

Ms. Chandni Maru
Company Secretary and Compliance Officer
M no. 60291

Date: October 26, 2026
Place: Mumbai

Evonile Pharma Limited

(formerly known as Novartis India Limited)

Annexure A

Appointment of Mr. Gagan Sharma, President – Specialty Business as a Senior Management Personnel

Reason for change viz. Appointment, reappointment, resignation, removal, death or otherwise	Appointment
Date of appointment & term of appointment	October 26, 2026
Brief Profile	Mr. Gagan Sharma is a senior pharmaceutical leader with over 30 years of extensive experience across diverse commercial functions, he brings a strong track record of driving strategic growth, leading business transformation, and building sustainable competitive advantage. Recognized for navigating complex business environments and translating strategy into results, he has successfully led high-performing teams, developed future leaders, and accelerated brand performance through innovative commercial models and integrated omnichannel strategies. His expertise spans global product launches, portfolio management, brand revitalization, market shaping, and commercial excellence across specialty and established brands. Most recently, he served as Therapy Area Head – Gene Therapy, Immunology and In-Market Brands at Novartis Healthcare Private Limited, where he was a member of the India Leadership Team.
Disclosure of directorship between Directors (in case of appointment of Director)	Not applicable